Stratasys Ltd and CollPlant Biotechnologies have announced a joint development and commercialisation agreement to collaborate on the development of a solution to bio-fabrication human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant’s regenerative breast implants program.
The new bioprinter, based on Stratasys’ precise P3™ 3D printing technology in combination with CollPlant’s flagship bioinks, will enable the production of CollPlant’s state of the art breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response, providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.
Under the agreement, both companies have agreed to cross-promote each other’s bioprinting products. Stratasys’s bioprinter will be offered to customers together with CollPlant’s bioinks, and similarly Stratasys’ bioprinter will be offered to CollPlant’s business partners and customers.
Through this partnership with CollPlant, there is an important opportunity to transform healthcare with bioprinting to improve the lives of patients undergoing breast augmentation or reconstruction procedures, informs Yoav Zeif, Stratasys, CEO. This agreement is well-aligned with Stratasys’ strategy to deliver complete solutions for high-growth industry applications with its ecosystem of partners. The production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerization technology are a particularly strong fit for bioprinting applications. He further believes that partnering with CollPlant will enable them to accelerate the industrialisation of bioprinting for regenerative medicine, the company looks forward to collaborating towards the successful commercialisation of CollPlant’s novel regenerative breast implants and beyond.
As per Yehiel Tal, CEO, CollPlant, the P3 technology allows printing with high resolution and process control, and the combined, pioneering technologies of both companies will streamline the development and production process so that there are efficient means to produce the regenerative breast implants and other potential tissues and organs. He believes that the rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer.